1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 9,670 | 9,990 | 14:24 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Devyser Diagnostics AB: Devyser secures a four-year tender in France for Devyser Compact | 46 | GlobeNewswire (Europe) | Devyser, a leading provider of advanced genetic testing solutions, has been awarded a new tender in Marseille, France, valued up to SEK 9.5 million over a 48-month period.
This tender with Assistance... ► Artikel lesen | |
| Do | Devyser Diagnostics AB: Health Canada grants IVD approval to Devyser's NGS-based chimerism test, the first of its kind in Canada | 79 | GlobeNewswire (Europe) | Devyser is proud to announce that One Lambda Devyser Chimerism and Advyser Chimerism have been granted approval as Class III In Vitro Diagnostic (IVD) medical devices by Health Canada. With this we... ► Artikel lesen | |
| DEVYSER DIAGNOSTICS Aktie jetzt für 0€ handeln | |||||
| 28.11. | Devyser Diagnostics AB: Devyser strengthens U.S. market presence with CMS pricing for PrenatalDetect RHD test | 724 | GlobeNewswire (Europe) | Devyser today announced that the Centers for Medicare & Medicaid Services (CMS) has issued its final pricing determination for the company's PrenatalDetect RHD test (CPT 0536U) at $192. The non-invasive... ► Artikel lesen | |
| 25.11. | Devyser Diagnostics AB: Devyser advances U.S. clinical strategy with first patient enrolled in Devyser Accept cfDNA study | 253 | GlobeNewswire (Europe) | Devyser today announced the enrollment of the first patient in its Devyser Accept cfDNA clinical trial, a key milestone in the company's efforts to bring a targeted next-generation sequencing solution... ► Artikel lesen | |
| 05.11. | Devyser Diagnostics AB: Devyser Diagnostics AB publishes quarterly report for the period July to September 2025 | 105 | GlobeNewswire (Europe) | "I took over as the new CEO of Devyser on August 4th and it has been an exciting and eventful time. We are continuing to launch unique products and sign cooperation agreements with major companies in... ► Artikel lesen | |
| 04.11. | Devyser Diagnostics AB: Devyser CFTR achieves IVDR compliance, strengthening clinical confidence in cystic fibrosis diagnostics | 245 | GlobeNewswire (Europe) | Devyser, a pioneer in advanced genetic testing solutions, is pleased to announce that its next-generation sequencing (NGS) based CFTR assay is now compliant under the European In Vitro Diagnostic Regulation... ► Artikel lesen | |
| 22.09. | Devyser Diagnostics AB: Bulletin from an Extraordinary General Meeting in Devyser Diagnostics AB (publ) held on 22 September 2025 | 120 | GlobeNewswire (Europe) | An Extraordinary General Meeting of Devyser Diagnostics AB (publ) ("Devyser" or the "Company") was held on Monday, 22 September 2025 at Bränningevägen 12, 120 54 Årsta. The main resolution passed at... ► Artikel lesen | |
| 15.08. | Devyser im zweiten Quartal 2025: Umsatz steigt um 27 % bei Rückkehr in die Gewinnzone | 1 | Investing.com Deutsch | ||
| 15.08. | Devyser Q2 2025 presentation: Revenue jumps 27% as profitability returns | 3 | Investing.com | ||
| 22.07. | Devyser Diagnostics AB: Devyser Diagnostics AB publishes quarterly report for the period April to June 2025 | 187 | GlobeNewswire (Europe) | "A positive operating result was recorded in the second quarter. The effects of the cost-cutting program initiated at the beginning of the year can already be seen in both current costs and in the cost... ► Artikel lesen | |
| 30.06. | Devyser Diagnostics AB: Devyser launches Genomic Blood Typing assay: All blood groups, one simple test | 198 | GlobeNewswire (Europe) | Devyser today announced the global launch of Devyser Genomic Blood Typing, a next-generation sequencing (NGS)-based solution that redefines molecular blood group research. Developed exclusively, this... ► Artikel lesen | |
| 29.04. | Devyser Diagnostics AB: Devyser Diagnostics AB publishes quarterly report for the period January to March 2025 | 412 | GlobeNewswire (Europe) | "A quarter has passed since I took over as acting CEO and it has been an eventful first few months. Despite the turbulent environment, marked by geopolitical uncertainty, we are able to report our second... ► Artikel lesen | |
| 14.04. | Devyser Diagnostics AB: Jan Wahlström new CEO for Devyser | 282 | GlobeNewswire (Europe) | Devyser's board has appointed Jan Wahlström as new CEO, effective August 4.Jan Wahlström has a long background in leading and developing companies in the Health Care and Life Science areas internationally.... ► Artikel lesen | |
| 19.02. | Devyser Diagnostics AB: Devyser secures a major SEK 16.8M tender in Italy with 30% growth | 277 | GlobeNewswire (Europe) | Devyser a leading provider of genetic testing solutions, has been awarded a significant tender for the supply of its comprehensive next-generation sequencing (NGS) tests for critical genetic markers.... ► Artikel lesen | |
| 13.02. | Devyser Diagnostics AB: Devyser Diagnostics AB publishes year-end report for January to December 2024 | 417 | GlobeNewswire (Europe) | "Net sales increased during the fourth quarter by 41.5 percent to SEK 64.2 million, compared with the corresponding quarter of 2023. The growth and strong performance are a result of robust development... ► Artikel lesen | |
| 28.01. | Devyser Diagnostics AB: Devyser wins tender in Italy for its cystic fibrosis NGS test worth up to 5.4 million SEK | 229 | GlobeNewswire (Europe) | Devyser has secured a tender for its cystic fibrosis NGS test, Devyser CFTR. The tender with Policlinico di Bari is valid for five years with an estimated total order value up to 5.4 million SEK
"This... ► Artikel lesen | |
| 16.01. | Devyser Diagnostics AB: Devyser publishes preliminary result for Q4 2024 | 752 | GlobeNewswire (Europe) | In light of this morning's communication that Fredrik Alpsten is leaving his position as CEO of Devyser and to avoid speculation, Devyser is releasing a summary of the year-end report for 2024 before... ► Artikel lesen |
17 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MEDTRONIC | 85,64 | -0,06 % | FDA Clears Medtronic's Hugo Robotic-Assisted Surgery System For Urologic Procedures | WASHINGTON (dpa-AFX) - Medtronic (MDT) announced that it has received FDA clearance for its Hugo robotic-assisted surgery (RAS) system in urologic procedures, marking a significant milestone... ► Artikel lesen | |
| HCA HEALTHCARE | 417,50 | -0,64 % | HCA Healthcare Provides $4.8 Million Gift To Support Launch Of Pepperdine University School Of Nursing | ||
| LANTHEUS | 52,40 | +0,11 % | Lantheus Holdings, Inc.: Lantheus Reports Third Quarter 2025 Financial Results and Provides Business Update | Recorded third quarter 2025 worldwide revenue of $384.0 million, GAAP fully diluted earnings per share of $0.41, adjusted fully diluted earnings per share of $1.27 and free cash flow of $94.7 millionSeparately... ► Artikel lesen | |
| ENVISTA | 17,600 | -1,12 % | Envista Holdings Corporation: Envista Reports Third Quarter 2025 Results | BREA, Calif., Oct. 29, 2025 /PRNewswire/ -- Envista Holdings Corporation (NYSE: NVST) today announced results for the quarter ended September 26, 2025."This was another strong quarter... ► Artikel lesen | |
| CAREDX | 16,370 | +0,52 % | CareDx, Inc.: CareDx präsentiert neue IVD-Produkte und IVDR-Zertifizierung für AlloSeq Tx und QTYPE bei der Jahrestagung 2025 der American Society of Histocompatibility & Immunogenetics | Festigung der weltweiten Führungsrolle bei der HLA-Typisierung von Spenderorganen und Transplantatempfängern
CareDx, Inc. (Nasdaq: CDNA) The Transplant Company ein führendes Unternehmen auf dem... ► Artikel lesen | |
| GT BIOPHARMA | 0,545 | 0,00 % | GT Biopharma, Inc. Offers Near-Term Catalyst Opportunity with Advancing Phase 1 Trials | NAPLES, FL / ACCESS Newswire / November 19, 2025 / Patients battling aggressive blood cancers face limited treatment options and uncertain outcomes. Scientists have increasingly turned to the body's... ► Artikel lesen | |
| SYNEOS HEALTH | - | - | Research Solutions, Inc.: Research Solutions Reports First Quarter Fiscal Year 2026 Results | Reports 21% Increase in ARR to $21.3 Million, Strong Growth in Net Income, Adjusted EBITDA and Operating Cash Flow
HENDERSON, Nev., Nov. 13, 2025 /PRNewswire/... ► Artikel lesen | |
| CARMAT | 0,099 | -100,00 % | CARMAT Provides an Update on the Ongoing Receivership Procedure | The Versailles Economic Court has opted for the takeover bid within the context of a sales plan submitted by CARMAT SAS and approved the sale plan1 of CARMAT SA to CARMAT SAS
Regulatory News:
CARMAT... ► Artikel lesen | |
| CHEMOMETEC | 97,10 | -0,41 % | Chemometec A/S: Growth in revenue and operating profit | Trading statement for Q1 2025/26 (1 July - 30 September 2025) Growth in revenue and operating profit Revenue was up by 8% in Q1 2025/26 (11% at constant exchange rates) to DKK 124.6 million from DKK... ► Artikel lesen | |
| ARRAIL GROUP | 0,203 | -100,00 % | XFRA I1D: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:
THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:
INSTRUMENT NAME Waehrung/Currency ISIN BIS/UNTIL
ARRAIL... ► Artikel lesen | |
| POLAREAN IMAGING | 0,001 | 0,00 % | Polarean: XENOVIEW 3T coil passes Philips compatibility testing | ||
| SIEMENS HEALTHINEERS | 43,190 | -1,28 % | JPMORGAN stuft Siemens Healthineers auf 'Overweight' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Siemens Healthineers nach dem jährlichen Treffen der US-Radiologen mit einem Kursziel von 61,30 Euro auf "Overweight" belassen.... ► Artikel lesen | |
| ALIGNMENT HEALTHCARE | 19,210 | 0,00 % | Alignment Healthcare Reports Third Quarter 2025 Results, Surpasses High-End of Guidance Across All Key Metrics | Reports Q3 revenue of $993.7 million, up 43.5% year-over-yearBeats high end of third quarter guidance and raises full-year outlook across all key metrics: membership, revenue, adjusted gross profit... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 39,500 | +1,26 % | EQS-PVR: Fresenius Medical Care AG: Veröffentlichung über Erwerb oder Veräußerung eigener Aktien nach § 40 Abs. 1 Satz 2 WpHG | EQS Stimmrechtsmitteilung: Fresenius Medical Care AG
Fresenius Medical Care AG: Veröffentlichung über Erwerb oder Veräußerung eigener Aktien nach § 40 Abs. 1 Satz 2 WpHG
03.12.2025... ► Artikel lesen | |
| CERIBELL | 21,220 | 0,00 % | Ceribell Receives FDA 510(k) Clearance for First-of-its-Kind Delirium Monitoring Solution | SUNNYVALE, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) ("Ceribell"), a medical technology company focused on transforming the diagnosis and management of patients with... ► Artikel lesen |
DEVYSER DIAGNOSTICS AB gehört der Branche Gesundheitswesen an. Der aktuelle Kurs liegt bei 9,510 Euro und damit +1,06 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu DEVYSER DIAGNOSTICS AB finden Sie auf Wallstreet Online.